MARKET

HAE

HAE

Haemonetics
NYSE

Real-time Quotes | Nasdaq Last Sale

62.88
+0.13
+0.21%
Opening 10:12 06/21 EDT
OPEN
62.89
PREV CLOSE
62.75
HIGH
63.10
LOW
62.33
VOLUME
133.91K
TURNOVER
--
52 WEEK HIGH
142.11
52 WEEK LOW
49.26
MARKET CAP
3.20B
P/E (TTM)
40.55
1D
5D
1M
3M
1Y
5Y
Is Weakness In Haemonetics Corporation (NYSE:HAE) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Haemonetics' (NYSE:HAE) recent performance, when its stock has declined 45...
Simply Wall St. · 1d ago
Haemonetics: Is This Pharma Stock A Hidden Gem?
Haemonetics (HAE) is a healthcare company that develops and sells products and solutions for hematology through three business segments: Plasma, Blood Center, and Hospital. The main value for HAE comes from its positioning as the leading producer of blood ...
TipRanks · 1d ago
CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action
Christian Kaspar-Bartke/Getty Images News BofA downgrades CureVac following disappointing COVID vaccine data Following the release yesterday of disappointing data in a phase 2b/3 trial of its COVID-19 vaccine, BofA Securities
Seekingalpha · 4d ago
Citigroup Starts Haemonetics at Buy With $75 Price Target
MT Newswires · 4d ago
Insider Trends: Haemonetics Insider Disposition Interrupting 90-Day Buy Trend
MT Newswires · 06/09 16:46
Haemonetics Stock Appears To Be Significantly Undervalued
GuruFocus News · 06/08 20:00
KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study
KalVista Pharmaceuticals (KALV) announces clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema ((HAE)) at the 12th C1-Inhibitor Deficiency & Angioedema Workshop. An analysis of the pharmacokinetic
Seekingalpha · 06/07 07:15
Blood Bags Market Share, Growth By Top Company, Region, Applications, Drivers, Trends & Forecast
Japan, Japan, Tue, 25 May 2021 01:14:27 / Comserve Inc. / -- Blood Bags Market With Top Countries Data, Industry Analysis , Size, Share, Revenue, Prominent Players, Developing Technologies, Tendencies and Forecast
Comserve · 05/25 05:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HAE. Analyze the recent business situations of Haemonetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HAE stock price target is 80.29 with a high estimate of 90.00 and a low estimate of 71.00.
EPS
Institutional Holdings
Institutions: 474
Institutional Holdings: 54.08M
% Owned: 106.14%
Shares Outstanding: 50.96M
TypeInstitutionsShares
Increased
98
3.20M
New
53
1.40M
Decreased
102
3.73M
Sold Out
39
895.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.89%
Healthcare Equipment & Supplies
+0.64%
Key Executives
Chairman/Independent Director
Richard Meelia
President/Chief Executive Officer/Director
Christopher Simon
Chief Financial Officer/Executive Vice President
William Burke
Executive Vice President/Chief Technology Officer
Said Bolorforosh
Executive Vice President/Chief Technology Officer
Anila Lingamneni
Executive Vice President/General Counsel
Michelle Basil
Senior Vice President
Josep Llorens
Independent Director
Robert Abernathy
Independent Director
Catherine Burzik
Independent Director
Michael Coyle
Independent Director
Charles Dockendorff
Independent Director
Mark Kroll
Independent Director
Claire Pomeroy
Independent Director
Ellen Zane
No Data
About HAE
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Webull offers kinds of Haemonetics Corporation stock information, including NYSE:HAE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HAE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HAE stock methods without spending real money on the virtual paper trading platform.